22 related articles for article (PubMed ID: 15685929)
1.
Ghasemi M; Reiazi N; Behzad-Behbahani A; Takhshid MA
Avicenna J Med Biotechnol; 2024; 16(1):34-39. PubMed ID: 38605743
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of epirubicin to cancerous cell using copper sulphide nanoparticle coated with polyarginine and 5TR1 aptamer.
Alizadeh F; Yaghoobi E; Imanimoghadam M; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
J Drug Target; 2023 Dec; 31(9):986-997. PubMed ID: 37869893
[TBL] [Abstract][Full Text] [Related]
3. From nature to cancer therapy: Evaluating the Streptomyces clavuligerus secondary metabolites for potential protein kinase inhibitors.
Saini R; Kumari S; Singh A; Mishra A
J Cell Biochem; 2024 Jan; 125(1):59-78. PubMed ID: 38047468
[TBL] [Abstract][Full Text] [Related]
4. Function of Epirubicin-Conjugated Polymeric Micelles in Sonodynamic Therapy.
Takemae K; Okamoto J; Horise Y; Masamune K; Muragaki Y
Front Pharmacol; 2019; 10():546. PubMed ID: 31164824
[TBL] [Abstract][Full Text] [Related]
5. New thiophene-1,3,4-oxadiazole-thiazolidine-2,4-dione hybrids: Synthesis, MCF-7 inhibition and binding studies.
Doddagaddavalli MA; Kalalbandi VKA; Seetharamappa J; Joshi SD
Bioorg Chem; 2024 Feb; 143():107003. PubMed ID: 38029570
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting autophagy increases epirubicin's cytotoxicity in breast cancer cells.
Guo W; Wang Y; Wang Z; Wang YP; Zheng H
Cancer Sci; 2016 Nov; 107(11):1610-1621. PubMed ID: 27560771
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin: Biological Properties, Analytical Methods, and Drug Delivery Nanosystems.
Luiz MT; Dutra JAP; Di Filippo LD; Junior AGT; Tofani LB; Marchetti JM; Chorilli M
Crit Rev Anal Chem; 2023; 53(5):1080-1093. PubMed ID: 34818953
[TBL] [Abstract][Full Text] [Related]
8. Differential oxygen radical susceptibility of adriamycin-sensitive and -resistant MCF-7 human breast tumor cells.
Mimnaugh EG; Dusre L; Atwell J; Myers CE
Cancer Res; 1989 Jan; 49(1):8-15. PubMed ID: 2535695
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of antioxidant enzymes against drug cytotoxicity in MCF-7 cells.
Ozkan A; Fiskin K
Exp Oncol; 2006 Mar; 28(1):86-8. PubMed ID: 16614716
[TBL] [Abstract][Full Text] [Related]
11. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
[TBL] [Abstract][Full Text] [Related]
12. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines.
Azab SS; El-Demerdash E; Abdel-Naim AB; Youssef E; El-Sharkawy N; Osman AM
Biochem Pharmacol; 2005 Sep; 70(5):725-32. PubMed ID: 16005435
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells.
Ozkan A; Ayhan A; Fiskin K
Cell Biol Toxicol; 2004 Sep; 20(5):261-71. PubMed ID: 15685929
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
